David Alan Preiss, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 14 | 2022 | 3245 | 1.540 |
Why?
|
| Anticholesteremic Agents | 9 | 2020 | 966 | 1.340 |
Why?
|
| Diabetic Angiopathies | 5 | 2019 | 803 | 1.320 |
Why?
|
| Diabetes Mellitus | 13 | 2019 | 5840 | 1.190 |
Why?
|
| Cardiovascular Diseases | 25 | 2022 | 15500 | 1.080 |
Why?
|
| Hypolipidemic Agents | 3 | 2015 | 609 | 1.030 |
Why?
|
| Cholesterol, LDL | 7 | 2020 | 2382 | 0.900 |
Why?
|
| Hypercholesterolemia | 3 | 2017 | 1141 | 0.740 |
Why?
|
| Diabetes Mellitus, Type 2 | 19 | 2023 | 12148 | 0.720 |
Why?
|
| Hypertriglyceridemia | 2 | 2014 | 293 | 0.690 |
Why?
|
| Cholesterol | 3 | 2015 | 2904 | 0.680 |
Why?
|
| Blood Glucose | 10 | 2020 | 6391 | 0.650 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2019 | 113 | 0.600 |
Why?
|
| Cyclohexanes | 3 | 2015 | 152 | 0.580 |
Why?
|
| Body Weight | 3 | 2017 | 4618 | 0.560 |
Why?
|
| Motor Activity | 3 | 2015 | 2715 | 0.540 |
Why?
|
| Capnography | 1 | 2017 | 91 | 0.540 |
Why?
|
| Phenylalanine | 3 | 2015 | 366 | 0.530 |
Why?
|
| Pancreatitis | 2 | 2013 | 1096 | 0.520 |
Why?
|
| Hypoglycemic Agents | 7 | 2019 | 3085 | 0.510 |
Why?
|
| Glucose Intolerance | 3 | 2015 | 575 | 0.510 |
Why?
|
| Respiratory Rate | 1 | 2017 | 176 | 0.510 |
Why?
|
| Triglycerides | 3 | 2013 | 2461 | 0.500 |
Why?
|
| Clinical Chemistry Tests | 1 | 2015 | 59 | 0.490 |
Why?
|
| Niacin | 1 | 2015 | 118 | 0.470 |
Why?
|
| Diabetic Nephropathies | 3 | 2019 | 973 | 0.470 |
Why?
|
| Gangrene | 1 | 2014 | 91 | 0.470 |
Why?
|
| Tetrazoles | 3 | 2017 | 909 | 0.460 |
Why?
|
| Fibric Acids | 1 | 2012 | 27 | 0.410 |
Why?
|
| Risk Reduction Behavior | 4 | 2020 | 1112 | 0.410 |
Why?
|
| Heart Failure | 11 | 2017 | 11669 | 0.410 |
Why?
|
| Valine | 1 | 2013 | 408 | 0.390 |
Why?
|
| Actigraphy | 2 | 2015 | 520 | 0.380 |
Why?
|
| Monitoring, Ambulatory | 1 | 2014 | 354 | 0.370 |
Why?
|
| Diabetic Neuropathies | 1 | 2014 | 405 | 0.360 |
Why?
|
| Lipoproteins | 2 | 2014 | 881 | 0.350 |
Why?
|
| Dyslipidemias | 2 | 2015 | 868 | 0.350 |
Why?
|
| Diabetes Complications | 2 | 2016 | 1315 | 0.350 |
Why?
|
| Monitoring, Physiologic | 3 | 2017 | 1779 | 0.340 |
Why?
|
| Antibodies, Monoclonal | 5 | 2017 | 9177 | 0.340 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2015 | 395 | 0.340 |
Why?
|
| Coronary Disease | 3 | 2020 | 5914 | 0.340 |
Why?
|
| Respiratory Muscles | 1 | 2009 | 142 | 0.320 |
Why?
|
| Spironolactone | 1 | 2012 | 412 | 0.310 |
Why?
|
| Respiration | 3 | 2017 | 1657 | 0.310 |
Why?
|
| Glucose Tolerance Test | 4 | 2016 | 1178 | 0.300 |
Why?
|
| Blood Pressure | 6 | 2023 | 8481 | 0.290 |
Why?
|
| Walking | 1 | 2014 | 1198 | 0.280 |
Why?
|
| Physical Endurance | 1 | 2009 | 366 | 0.280 |
Why?
|
| Metformin | 2 | 2014 | 906 | 0.270 |
Why?
|
| Risk Factors | 26 | 2020 | 74206 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 15 | 2019 | 10209 | 0.270 |
Why?
|
| Fatty Liver | 2 | 2010 | 790 | 0.260 |
Why?
|
| Multifactorial Inheritance | 1 | 2014 | 1387 | 0.250 |
Why?
|
| Humans | 77 | 2023 | 761504 | 0.250 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2019 | 857 | 0.250 |
Why?
|
| Oxygen | 1 | 2017 | 4227 | 0.250 |
Why?
|
| Troponin T | 3 | 2019 | 780 | 0.250 |
Why?
|
| Diabetic Retinopathy | 1 | 2014 | 1274 | 0.240 |
Why?
|
| Cardiac Output, Low | 2 | 2015 | 191 | 0.240 |
Why?
|
| Troponin I | 2 | 2019 | 651 | 0.230 |
Why?
|
| Stroke | 3 | 2015 | 9757 | 0.220 |
Why?
|
| Anesthesia | 3 | 2021 | 1594 | 0.220 |
Why?
|
| Mass Screening | 3 | 2018 | 5428 | 0.220 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2023 | 109 | 0.210 |
Why?
|
| Research Design | 4 | 2016 | 6180 | 0.190 |
Why?
|
| Exercise Test | 1 | 2009 | 2127 | 0.190 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 8002 | 0.190 |
Why?
|
| Glucosides | 2 | 2023 | 512 | 0.180 |
Why?
|
| Anesthesiology | 2 | 2023 | 1117 | 0.180 |
Why?
|
| Respiration, Artificial | 3 | 2009 | 2628 | 0.170 |
Why?
|
| Esters | 1 | 2020 | 211 | 0.160 |
Why?
|
| Stroke Volume | 4 | 2017 | 5496 | 0.160 |
Why?
|
| Hyperlipidemias | 2 | 2015 | 771 | 0.160 |
Why?
|
| Equipment Design | 4 | 2019 | 3510 | 0.160 |
Why?
|
| Sulfhydryl Compounds | 1 | 2020 | 301 | 0.150 |
Why?
|
| Laryngeal Masks | 1 | 2019 | 101 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 2691 | 0.150 |
Why?
|
| Exercise | 3 | 2014 | 5890 | 0.150 |
Why?
|
| Male | 32 | 2020 | 360804 | 0.150 |
Why?
|
| Risk | 4 | 2014 | 9610 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7390 | 0.140 |
Why?
|
| Anesthesia Department, Hospital | 1 | 2017 | 69 | 0.140 |
Why?
|
| Amides | 1 | 2020 | 449 | 0.140 |
Why?
|
| Pharmacology, Clinical | 1 | 2016 | 22 | 0.140 |
Why?
|
| Models, Statistical | 2 | 2009 | 5079 | 0.140 |
Why?
|
| Risk Assessment | 8 | 2019 | 23995 | 0.140 |
Why?
|
| Myocardial Infarction | 3 | 2015 | 11460 | 0.140 |
Why?
|
| Electronic Health Records | 4 | 2017 | 4811 | 0.140 |
Why?
|
| Female | 32 | 2020 | 392644 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 2243 | 0.130 |
Why?
|
| Double-Blind Method | 5 | 2023 | 12341 | 0.130 |
Why?
|
| Middle Aged | 24 | 2020 | 220895 | 0.130 |
Why?
|
| Metabolomics | 2 | 2016 | 1659 | 0.130 |
Why?
|
| Body Mass Index | 6 | 2019 | 12953 | 0.130 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2016 | 89 | 0.130 |
Why?
|
| Muscular Diseases | 2 | 2017 | 553 | 0.130 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2015 | 82 | 0.120 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 15266 | 0.120 |
Why?
|
| Thermodynamics | 1 | 2017 | 595 | 0.120 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2015 | 169 | 0.120 |
Why?
|
| Biphenyl Compounds | 2 | 2017 | 1007 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2011 | 3408 | 0.120 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2014 | 60 | 0.120 |
Why?
|
| Incidence | 6 | 2020 | 21353 | 0.120 |
Why?
|
| Aortic Aneurysm | 1 | 2019 | 648 | 0.120 |
Why?
|
| Documentation | 1 | 2021 | 897 | 0.120 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2020 | 1007 | 0.120 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 6310 | 0.120 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 629 | 0.120 |
Why?
|
| Hyperkalemia | 1 | 2016 | 233 | 0.110 |
Why?
|
| Prediabetic State | 2 | 2020 | 545 | 0.110 |
Why?
|
| Enalapril | 1 | 2016 | 312 | 0.110 |
Why?
|
| Oximetry | 1 | 2017 | 459 | 0.110 |
Why?
|
| Video Recording | 1 | 2019 | 966 | 0.110 |
Why?
|
| Proteinuria | 1 | 2016 | 607 | 0.110 |
Why?
|
| Drug Dosage Calculations | 1 | 2013 | 117 | 0.110 |
Why?
|
| Laryngoscopy | 1 | 2019 | 706 | 0.110 |
Why?
|
| Aged | 20 | 2020 | 169289 | 0.110 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2013 | 186 | 0.100 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2016 | 1039 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2016 | 1516 | 0.100 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 12463 | 0.100 |
Why?
|
| Alanine Transaminase | 2 | 2011 | 603 | 0.100 |
Why?
|
| Disease Progression | 4 | 2016 | 13506 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 935 | 0.100 |
Why?
|
| Tunica Intima | 1 | 2013 | 459 | 0.090 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2005 | 411 | 0.090 |
Why?
|
| Age Distribution | 2 | 2015 | 2880 | 0.090 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 179 | 0.090 |
Why?
|
| Intubation, Intratracheal | 1 | 2019 | 1329 | 0.090 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2016 | 787 | 0.090 |
Why?
|
| American Heart Association | 1 | 2015 | 1039 | 0.090 |
Why?
|
| Insulin Resistance | 2 | 2014 | 3963 | 0.090 |
Why?
|
| Ventricular Function, Left | 2 | 2016 | 3879 | 0.080 |
Why?
|
| Gallstones | 1 | 2012 | 284 | 0.080 |
Why?
|
| Waist Circumference | 1 | 2013 | 935 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2015 | 2281 | 0.080 |
Why?
|
| Cause of Death | 3 | 2015 | 3683 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 1241 | 0.080 |
Why?
|
| Cohort Studies | 6 | 2020 | 41487 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2011 | 9646 | 0.080 |
Why?
|
| Canada | 1 | 2015 | 2122 | 0.080 |
Why?
|
| Clofibric Acid | 1 | 2008 | 8 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 10766 | 0.080 |
Why?
|
| Scotland | 2 | 2019 | 143 | 0.080 |
Why?
|
| Fasting | 1 | 2015 | 1603 | 0.080 |
Why?
|
| Prospective Studies | 8 | 2017 | 54425 | 0.080 |
Why?
|
| Secondary Prevention | 1 | 2015 | 1475 | 0.080 |
Why?
|
| Breath Tests | 1 | 2009 | 299 | 0.080 |
Why?
|
| Algorithms | 1 | 2008 | 14031 | 0.070 |
Why?
|
| Mortality | 2 | 2016 | 2901 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 3429 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 15936 | 0.070 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 1902 | 0.070 |
Why?
|
| Ventilators, Mechanical | 1 | 2009 | 288 | 0.070 |
Why?
|
| ROC Curve | 2 | 2016 | 3579 | 0.070 |
Why?
|
| Cardiovascular System | 1 | 2014 | 834 | 0.070 |
Why?
|
| Carbon Dioxide | 3 | 2005 | 1147 | 0.070 |
Why?
|
| Anesthesia, Closed-Circuit | 1 | 2005 | 14 | 0.070 |
Why?
|
| Respiratory Dead Space | 1 | 2005 | 31 | 0.070 |
Why?
|
| Treatment Outcome | 8 | 2019 | 64680 | 0.070 |
Why?
|
| Albuminuria | 1 | 2010 | 657 | 0.070 |
Why?
|
| Placental Circulation | 1 | 2005 | 37 | 0.060 |
Why?
|
| Fatigue | 1 | 2013 | 1552 | 0.060 |
Why?
|
| Hospitalization | 3 | 2017 | 10723 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 15842 | 0.060 |
Why?
|
| Comorbidity | 3 | 2016 | 10508 | 0.060 |
Why?
|
| Adult | 11 | 2022 | 221177 | 0.060 |
Why?
|
| Disease Management | 1 | 2015 | 2508 | 0.060 |
Why?
|
| Physicians | 1 | 2023 | 4591 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2014 | 3769 | 0.060 |
Why?
|
| Echocardiography | 1 | 2017 | 4989 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 2319 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2015 | 6343 | 0.060 |
Why?
|
| Anesthesia, Inhalation | 1 | 2004 | 220 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2014 | 2690 | 0.060 |
Why?
|
| Prognosis | 5 | 2019 | 29625 | 0.060 |
Why?
|
| Animals | 6 | 2019 | 168459 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 2024 | 0.060 |
Why?
|
| Life Style | 1 | 2015 | 3917 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2008 | 1380 | 0.060 |
Why?
|
| Benzhydryl Compounds | 2 | 2023 | 916 | 0.060 |
Why?
|
| Hyperoxia | 1 | 2005 | 258 | 0.050 |
Why?
|
| Ultrasonography, Doppler | 1 | 2005 | 462 | 0.050 |
Why?
|
| Time Factors | 4 | 2019 | 39967 | 0.050 |
Why?
|
| Young Adult | 3 | 2017 | 59243 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2013 | 1978 | 0.050 |
Why?
|
| Hyperglycemia | 1 | 2011 | 1376 | 0.050 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2004 | 137 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2015 | 3905 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2023 | 5880 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2008 | 2927 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2022 | 6240 | 0.050 |
Why?
|
| Uterus | 1 | 2005 | 649 | 0.050 |
Why?
|
| Masks | 1 | 2004 | 208 | 0.050 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 39106 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2013 | 3028 | 0.050 |
Why?
|
| Smoking | 3 | 2015 | 9053 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 4016 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2021 | 80636 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2004 | 1866 | 0.040 |
Why?
|
| Goals | 1 | 2023 | 711 | 0.040 |
Why?
|
| Hospital Departments | 1 | 2017 | 134 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2017 | 1723 | 0.040 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2005 | 1755 | 0.040 |
Why?
|
| Water | 1 | 2023 | 1411 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2010 | 22176 | 0.030 |
Why?
|
| Survival Rate | 1 | 2011 | 12725 | 0.030 |
Why?
|
| Prevalence | 2 | 2016 | 15732 | 0.030 |
Why?
|
| Adrenomedullin | 1 | 2016 | 85 | 0.030 |
Why?
|
| Reference Values | 2 | 2018 | 4920 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 20098 | 0.030 |
Why?
|
| Apolipoprotein B-100 | 1 | 2016 | 157 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 6403 | 0.030 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2016 | 350 | 0.030 |
Why?
|
| Glycopeptides | 1 | 2016 | 220 | 0.030 |
Why?
|
| Cross Infection | 1 | 2004 | 1422 | 0.030 |
Why?
|
| Cystatin C | 1 | 2016 | 269 | 0.030 |
Why?
|
| Liver | 1 | 2010 | 7529 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2022 | 1186 | 0.030 |
Why?
|
| Galectin 3 | 1 | 2016 | 240 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 695 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2016 | 412 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2011 | 4686 | 0.030 |
Why?
|
| Finland | 1 | 2015 | 607 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2009 | 9318 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 2017 | 5112 | 0.030 |
Why?
|
| Sex Factors | 2 | 2018 | 10552 | 0.030 |
Why?
|
| Age Factors | 3 | 2018 | 18395 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2004 | 3575 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2015 | 10090 | 0.030 |
Why?
|
| Operating Rooms | 1 | 2019 | 789 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 431 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 1572 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2016 | 1132 | 0.020 |
Why?
|
| Workflow | 1 | 2016 | 851 | 0.020 |
Why?
|
| Anesthetics | 1 | 2016 | 523 | 0.020 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2010 | 144 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1440 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2016 | 683 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2016 | 2048 | 0.020 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 58976 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 5492 | 0.020 |
Why?
|
| Hypertension | 1 | 2009 | 8540 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 1814 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 2176 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 2192 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2009 | 14666 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2023 | 4792 | 0.020 |
Why?
|
| Acute Coronary Syndrome | 1 | 2020 | 2190 | 0.020 |
Why?
|
| Obesity | 1 | 2009 | 12947 | 0.020 |
Why?
|
| United States | 1 | 2015 | 72334 | 0.020 |
Why?
|
| Forecasting | 1 | 2015 | 2928 | 0.020 |
Why?
|
| Hypocapnia | 1 | 2005 | 38 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2005 | 19 | 0.020 |
Why?
|
| Health Status | 1 | 2019 | 4077 | 0.020 |
Why?
|
| Umbilical Arteries | 1 | 2005 | 79 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 6814 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6484 | 0.020 |
Why?
|
| Blood Gas Analysis | 1 | 2005 | 379 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2017 | 3807 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2005 | 231 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 3826 | 0.010 |
Why?
|
| Patient Selection | 1 | 2016 | 4244 | 0.010 |
Why?
|
| Hypercapnia | 1 | 2005 | 261 | 0.010 |
Why?
|
| Middle Cerebral Artery | 1 | 2005 | 275 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 1702 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3092 | 0.010 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2005 | 379 | 0.010 |
Why?
|
| Tidal Volume | 1 | 2005 | 488 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12059 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2005 | 930 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2005 | 1371 | 0.010 |
Why?
|
| Respiratory Mechanics | 1 | 2005 | 699 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 26125 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2014 | 3537 | 0.010 |
Why?
|
| Aerosols | 1 | 2004 | 635 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2016 | 3429 | 0.010 |
Why?
|
| Kidney | 1 | 2016 | 7048 | 0.010 |
Why?
|
| Lipids | 1 | 2011 | 3341 | 0.010 |
Why?
|
| Arteries | 1 | 2005 | 1123 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 2477 | 0.010 |
Why?
|
| Child | 1 | 2008 | 80153 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 2850 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 12690 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 14605 | 0.010 |
Why?
|
| Logistic Models | 1 | 2013 | 13255 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 17904 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2010 | 5972 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 29874 | 0.000 |
Why?
|